» Articles » PMID: 19959717

Chronic Mineral Dysregulation Promotes Vascular Smooth Muscle Cell Adaptation and Extracellular Matrix Calcification

Overview
Specialty Nephrology
Date 2009 Dec 5
PMID 19959717
Citations 128
Authors
Affiliations
Soon will be listed here.
Abstract

In chronic kidney disease (CKD) vascular calcification occurs in response to deranged calcium and phosphate metabolism and is characterized by vascular smooth muscle cell (VSMC) damage and attrition. To gain mechanistic insights into how calcium and phosphate mediate calcification, we used an ex vivo model of human vessel culture. Vessel rings from healthy control subjects did not accumulate calcium with long-term exposure to elevated calcium and/or phosphate. In contrast, vessel rings from patients with CKD accumulated calcium; calcium induced calcification more potently than phosphate (at equivalent calcium-phosphate product). Elevated phosphate increased alkaline phosphatase activity in CKD vessels, but inhibition of alkaline phosphatase with levamisole did not block calcification. Instead, calcification in CKD vessels most strongly associated with VSMC death resulting from calcium- and phosphate-induced apoptosis; treatment with a pan-caspase inhibitor ZVAD ameliorated calcification. Calcification in CKD vessels was also associated with increased deposition of VSMC-derived vesicles. Electron microscopy confirmed increased deposition of vesicles containing crystalline calcium and phosphate in the extracellular matrix of dialysis vessel rings. In contrast, vesicle deposition and calcification did not occur in normal vessel rings, but we observed extensive intracellular mitochondrial damage. Taken together, these data provide evidence that VSMCs undergo adaptive changes, including vesicle release, in response to dysregulated mineral metabolism. These adaptations may initially promote survival but ultimately culminate in VSMC apoptosis and overt calcification, especially with continued exposure to elevated calcium.

Citing Articles

Patient characteristics modify the association between changes in mineral metabolism parameters and mortality in a nationwide hemodialysis cohort study.

Goto S, Hamano T, Taniguchi M, Abe M, Nitta K, Nishi S Sci Rep. 2025; 15(1):8089.

PMID: 40057535 PMC: 11890868. DOI: 10.1038/s41598-025-92359-0.


Mineral Stress Drives Loss of Heterochromatin: An Early Harbinger of Vascular Inflammaging and Calcification.

Ho C, Wu M, Thammaphet J, Ahmad S, Ho C S J, Draganova L Circ Res. 2025; 136(4):379-399.

PMID: 39840455 PMC: 11825498. DOI: 10.1161/CIRCRESAHA.124.325374.


Extracellular matrix in vascular homeostasis and disease.

Zhang L, Zhou J, Kong W Nat Rev Cardiol. 2025; .

PMID: 39743560 DOI: 10.1038/s41569-024-01103-0.


The functional role of soluble proteins acquired by extracellular vesicles.

Ramos A, Gobbi Sebinelli H, Ciancaglini P, Rosato N, Mebarek S, Buchet R J Extracell Biol. 2024; 1(1):e34.

PMID: 38938684 PMC: 11080634. DOI: 10.1002/jex2.34.


Hypertension and Cardiovascular Risk Among Children with Chronic Kidney Disease.

Larkins N, Craig J Curr Hypertens Rep. 2024; 26(10):389-398.

PMID: 38806767 PMC: 11416368. DOI: 10.1007/s11906-024-01308-1.


References
1.
Block G, Levin N, Port F . Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31(4):607-17. DOI: 10.1053/ajkd.1998.v31.pm9531176. View

2.
Block G, Spiegel D, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A . Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68(4):1815-24. DOI: 10.1111/j.1523-1755.2005.00600.x. View

3.
Schoppet M, Shanahan C . Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?. Kidney Int. 2008; 73(9):989-91. DOI: 10.1038/ki.2008.104. View

4.
Kim K . Apoptosis and calcification. Scanning Microsc. 1995; 9(4):1137-75; discussion 1175-8. View

5.
Thimm F, Czirfuzs A, Matyas S, Frey M . Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. J Cardiovasc Pharmacol. 1994; 24 Suppl 2:S75-84. View